Anna Turetsky joined The Mark Foundation as Principal, Venture Investments in November 2019. Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics, Gemini Therapeutics, Locana, Cyteir Therapeutics, and Disarm Therapeutics, and served as an Observer on the Boards of Directors of these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a PhD in Biophysics from Harvard University and a BA in Biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar. At Harvard, Anna completed her graduate research as an NSF Graduate Research Fellow in the Center for Systems Biology at Massachusetts General Hospital. Her interdisciplinary projects combined chemical biology, engineering, and translational medicine to develop novel cancer diagnostics.
